- Home
- SBFM vs RNAZ Comparison
SBFM vs RNAZ Comparison
Compare SBFM & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBFM
- RNAZ
- Stock Information
- Founded
- SBFM 2006
- RNAZ 2016
- Country
- SBFM United States
- RNAZ United States
- Employees
- SBFM N/A
- RNAZ N/A
- Industry
- SBFM Biotechnology: Pharmaceutical Preparations
- RNAZ Biotechnology: Pharmaceutical Preparations
- Sector
- SBFM Health Care
- RNAZ Health Care
- Exchange
- SBFM Nasdaq
- RNAZ Nasdaq
- Market Cap
- SBFM 6.6M
- RNAZ 6.1M
- IPO Year
- SBFM N/A
- RNAZ 2021
- Fundamental
- Price
- SBFM $1.39
- RNAZ $10.54
- Analyst Decision
- SBFM Strong Buy
- RNAZ Strong Buy
- Analyst Count
- SBFM 1
- RNAZ 1
- Target Price
- SBFM $15.00
- RNAZ $280.00
- AVG Volume (30 Days)
- SBFM 47.2K
- RNAZ 13.8K
- Earning Date
- SBFM 11-04-2025
- RNAZ 08-14-2025
- Dividend Yield
- SBFM N/A
- RNAZ N/A
- EPS Growth
- SBFM N/A
- RNAZ N/A
- EPS
- SBFM N/A
- RNAZ N/A
- Revenue
- SBFM $36,341,741.00
- RNAZ N/A
- Revenue This Year
- SBFM $32.20
- RNAZ N/A
- Revenue Next Year
- SBFM $32.74
- RNAZ N/A
- P/E Ratio
- SBFM N/A
- RNAZ N/A
- Revenue Growth
- SBFM 19.22
- RNAZ N/A
- 52 Week Low
- SBFM $1.17
- RNAZ $6.15
- 52 Week High
- SBFM $3.90
- RNAZ $739.20
- Technical
- Relative Strength Index (RSI)
- SBFM 44.01
- RNAZ 51.64
- Support Level
- SBFM $1.35
- RNAZ $10.00
- Resistance Level
- SBFM $1.45
- RNAZ $10.48
- Average True Range (ATR)
- SBFM 0.07
- RNAZ 0.67
- MACD
- SBFM -0.00
- RNAZ 0.03
- Stochastic Oscillator
- SBFM 27.78
- RNAZ 74.40
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.